Hey Manny... I think this got covered off recently in the...

Hey Manny...

I think this got covered off recently in the following thread...

https://hotcopper.com.au/threads/new-roth-report.3199739/?post_id=22288277#.WKI3gm99600

If you read in between the lines, you'll see they've (ROTH) effectively only priced VLA on the 'melanoma' indications, with no value attributed to the NSCLC & Bladder indications...

Let's see what happens once the April 'trial-data' is announced, I'm pretty sure you'll see brokers 're-rate' VLA again, ROTH previously had a $4.50 target on VLA, but that essentially included the 'spectrum' of initiated indications for CAVATAK...

ML